Literature DB >> 23271298

Topical propranolol hydrochloride gel for superficial infantile hemangiomas.

Lie Wang1, Yin Xia1, Yanan Zhai1, Chengjin Li2, Yiqing Li3.   

Abstract

The clinical efficacy and safety of topical propranolol hydrochloride gel in the treatment of superficial infantile hemangiomas (IHs) were assessed. Fifty-one cases of IHs from Oct. 2010 to Sept. 2011 were subjected to the topical propranolol hydrochloride gel intervention in Fuzhou General Hospital of Nanjing Military Commands, China. Changes in size, texture, color, peak systolic velocity of the hemangiomas, resistance index and adverse effects were observed. The results were evaluated by using Achauer system, and responses of IHs to pranpronolol were considered scale II (poor) in 4 patients (17.24%), scale II (moderate) in 18 patients (24.14%), scale III (good) in 22 patients (44.83%) and scale IV (excellent) in 7 patients (13.79%). The response of superficial hemangiomas was significantly better than other hemangiomas (P<0.05), and no differences in response were found among different primary sites (P>0.05). Our study indicates that topical application of 3% propranolol hydrochloride gel is effective and safe in treating IHs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23271298     DOI: 10.1007/s11596-012-1059-6

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  7 in total

Review 1.  Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action.

Authors:  C H Storch; P H Hoeger
Journal:  Br J Dermatol       Date:  2010-05-08       Impact factor: 9.302

2.  Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution.

Authors:  Tinte Itinteang; Helen D Brasch; Swee T Tan; Darren J Day
Journal:  J Plast Reconstr Aesthet Surg       Date:  2010-09-26       Impact factor: 2.740

3.  Propranolol for severe hemangiomas of infancy.

Authors:  Christine Léauté-Labrèze; Eric Dumas de la Roque; Thomas Hubiche; Franck Boralevi; Jean-Benoît Thambo; Alain Taïeb
Journal:  N Engl J Med       Date:  2008-06-12       Impact factor: 91.245

4.  Management of hemangioma of infancy: review of 245 patients.

Authors:  B M Achauer; C J Chang; V M Vander Kam
Journal:  Plast Reconstr Surg       Date:  1997-04       Impact factor: 4.730

5.  Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants.

Authors:  Marlies de Graaf; Johannes M P J Breur; Martine F Raphaël; Marike Vos; Corstiaan C Breugem; Suzanne G M A Pasmans
Journal:  J Am Acad Dermatol       Date:  2011-05-20       Impact factor: 11.527

6.  Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study.

Authors:  Alex Zvulunov; Catherine McCuaig; Ilona J Frieden; Anthony J Mancini; Kate B Puttgen; Magdalene Dohil; Gayle Fischer; Julie Powell; Bernard Cohen; Dan Ben Amitai
Journal:  Pediatr Dermatol       Date:  2011-03-01       Impact factor: 1.588

7.  Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas.

Authors:  Clemens Schiestl; Kathrin Neuhaus; Silke Zoller; Ulrike Subotic; Ishilde Forster-Kuebler; Rike Michels; Christian Balmer; Lisa Weibel
Journal:  Eur J Pediatr       Date:  2010-10-09       Impact factor: 3.183

  7 in total
  2 in total

1.  Effect of topical propranolol gel on plasma renin, angiotensin II and vascular endothelial growth factor in superficial infantile hemangiomas.

Authors:  Yu-Juan Tang; Zai-Zhong Zhang; Shao-Quan Chen; Shu-Ming Chen; Cheng-Jin Li; Jian-Wei Chen; Bo Yuan; Yin Xia; Lie Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

2.  The Influence of Formulation and Excipients on Propranolol Skin Permeation and Retention.

Authors:  Cristina Padula; Sara Nicoli; Silvia Pescina; Patrizia Santi
Journal:  Biomed Res Int       Date:  2018-08-02       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.